Literature DB >> 14533007

RB1CC1 suppresses cell cycle progression through RB1 expression in human neoplastic cells.

Keiichi Kontani1, Tokuhiro Chano, Yoshitomo Ozaki, Noriaki Tezuka, Satoru Sawai, Shozo Fujino, Yukikazu Saeki, Hidetoshi Okabe.   

Abstract

RB1-inducible Coiled-Coil 1 (RB1CC1) is a putative transcription factor that functions as a key regulator of retinoblastoma 1 (RB1). RB1CC1 mutations lacking this function are involved in the tumorigenesis of breast cancers. RB1CC1 is distributed in various tissues other than the breast, and is thought to play a biological role in controlling cell growth and progression of various cancers. The present study examined the correlation between RB1CC1 and cell cycle-related molecules in human neoplastic cells, and the ratios of cells at various phases of the cell cycle were verified in the RB1CC1-transduced human leukemic cell lines, K562 and Jurkat. The results showed that RB1CC1 was synchronously expressed with RB1 in various cell lines and that introducing RB1CC1 induced RB1 expression in human leukemic cell lines, although independently of the other molecules. Western blotting showed that underphosphorylated forms of RB1 were elicited by RB1CC1, whereas E2F1 was not affected. Cell cycle analysis demonstrated that G2-M phases were suppressed in RB1CC1-transduced cells. These data suggested that RB1CC1 induces the expression of RB1, especially of underphosphorylated forms, then suppresses cell cycle progression in human neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14533007

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  10 in total

Review 1.  FIP200, a key signaling node to coordinately regulate various cellular processes.

Authors:  Boyi Gan; Jun-Lin Guan
Journal:  Cell Signal       Date:  2007-11-01       Impact factor: 4.315

2.  The ETS factor TEL2 is a hematopoietic oncoprotein.

Authors:  Cintia Carella; Mark Potter; Jacqueline Bonten; Jerold E Rehg; Geoffrey Neale; Gerard C Grosveld
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

3.  An ensemble prognostic model for colorectal cancer.

Authors:  Bi-Qing Li; Tao Huang; Jian Zhang; Ning Zhang; Guo-Hua Huang; Lei Liu; Yu-Dong Cai
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

4.  Preparation of mouse monoclonal antibody for RB1CC1 and its clinical application.

Authors:  Yusuke Hama; Tokuhiro Chano; Takuma Inui; Kyoichi Matsumoto; Hidetoshi Okabe
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

5.  Identification of FIP200 interaction with the TSC1-TSC2 complex and its role in regulation of cell size control.

Authors:  Boyi Gan; Zara K Melkoumian; Xiaoyang Wu; Kun-Liang Guan; Jun-Lin Guan
Journal:  J Cell Biol       Date:  2005-07-25       Impact factor: 10.539

6.  Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.

Authors:  Gloria Pelizzo; Luigi Chiricosta; Emanuela Mazzon; Gian Vincenzo Zuccotti; Maria Antonietta Avanzini; Stefania Croce; Mario Lima; Placido Bramanti; Valeria Calcaterra
Journal:  Pediatr Rep       Date:  2021-01-05

7.  Tumour cells are sensitised to ferroptosis via RB1CC1-mediated transcriptional reprogramming.

Authors:  Xiangfei Xue; Lifang Ma; Xiao Zhang; Xin Xu; Susu Guo; Yikun Wang; Shiyu Qiu; Jiangtao Cui; Wanxin Guo; Yongchun Yu; Fenyong Sun; Yi Shi; Jiayi Wang
Journal:  Clin Transl Med       Date:  2022-02

8.  Gene expression profile of glioblastoma peritumoral tissue: an ex vivo study.

Authors:  Annunziato Mangiola; Nathalie Saulnier; Pasquale De Bonis; Daniela Orteschi; Gigliola Sica; Gina Lama; Benedetta Ludovica Pettorini; Giovanni Sabatino; Marcella Zollino; Libero Lauriola; Anna Colabianchi; Gabriella Proietti; Gyula Kovacs; Giulio Maira; Carmelo Anile
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer.

Authors:  Mahipal V Suraneni; John R Moore; Dingxiao Zhang; Mark Badeaux; Marc D Macaluso; John DiGiovanni; Donna Kusewitt; Dean G Tang
Journal:  Cell Cycle       Date:  2014-04-14       Impact factor: 4.534

10.  Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Authors:  Yasuhiko Ohshio; Koji Teramoto; Jun Hanaoka; Noriaki Tezuka; Yasushi Itoh; Tohru Asai; Yataro Daigo; Kazumasa Ogasawara
Journal:  Cancer Sci       Date:  2015-01-16       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.